Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 463 results found. Search for [ Dr Reddy's Laboratories ]

Results 360 to 380 of 463
E. Kumar Sharma
April 7, 2014
In what is being described by a landmark deal in Indian pharma, Sun Pharma and Ranbaxy announced that Sun Pharma is to acquire Ranbaxy in an all stock $ 4 billion deal. According to a release from Sun Pharma, it is to create world's 5th largest specialty generic pharma company, the number one pharma company in the US and in India.


Bill Berkrot
New York, March 26, 2014
Analysts say in the short term, the recent troubles are expected to benefit larger global competitors, such as Teva Pharmaceutical Industries, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India.


Toni Clarke and Bill Berkrot
Washington/New York, March 19, 2014
India supplies about 40 per cent of generic and over-the-counter drugs used in the United States, making it the second-biggest supplier after Canada.


PTI
Mumbai, March 18, 2014
After climbing to all-time intra-day high during the session, the 30-share Sensex ended higher by just 22.81 points, or 0.10 per cent, at 21,832.61 - its second straight session of gains.


Zeba Siddiqui
Mumbai, March 13, 2014
The US Food and Drug Administration says it is a \"Class II\" recall, which indicates a remote chance of severe adverse consequences or death due to the product flaw.


E. Kumar Sharma
February 11, 2014
This was mainly due to higher realisations, following the launch of some key limited competition product in the US market. Its net profit for the corresponding quarter in the previous financial year had been Rs 378.2 crore.


PTI
New Delhi, February 11, 2014
Consolidated net sales rose to Rs 3,533.76 crore in the quarter under review from Rs 2,865.16 crore a year earlier, Dr Reddy's Laboratories said in a BSE filing.


Mahesh Nayak
February 10, 2014
A stable government at the centre after the election will be a key catalyst for the resurgence of the market. The Indian market may remain volatile until the elections but that gives an opportunity to build a strong portfolio.


E. Kumar Sharma
January 15, 2014
Dr. Reddy's Laboratories and US-based biopharmaceutical company Galena Biopharma announced on Wednesday that they have entered into a development and commercialisation partnership to develop and commercialise the drug NeuVax (nelipepimut-S) in India.


E. Kumar Sharma
January 10, 2014
Dr Reddy's Laboratories on Friday announced the launch of a combination drug to treat hypertension, or high blood pressure.


E. Kumar Sharma
January 7, 2014
\"Our educational institutions are still not the hotbeds of innovation... We need to move away from being graduate-producing factories to being creators of innovative knowledge.\" GV Prasad, Chairman and CEO of Dr Reddy's Laboratories, said at an event in Pilani.


E Kumar Sharma
December 30, 2013
The Indian pharmaceutical industry faces a crucial new year. Until now, the local industry has largely followed a growth model that focused on launching cheap generic versions of branded innovator drugs made by global pharmaceutical companies.


N Madhavan
December 18, 2013
The way Indian pharmaceutical companies develop drugs is a model that should be followed across the world, said Anita McGahan, Professor of Strategic Management at Rotman School of Management in University of Toronto.


N. Madhavan
December 17, 2013
They have led their companies with elan and vigour, ensuring high growth despite the difficult economic environment. Business Today, with knowledge support from PwC India, presents India's Best CEOs in 2013.


BT Online Bureau
Mumbai, December 5, 2013
ICICI Bank and HDFC Bank shares together contributed 163 points to the gains on the Sensex, which was also lifted by Larsen & Toubro and Reliance Industries.


Manu Kaushik
December 4, 2013
Non-executive directors at Indian companies have not proved effective so far in improving corporate governance practices. They themselves are partly to blame.


E Kumar Sharma
October 31, 2013
Dr Reddy's Laboratories total revenue for the second quarter ended September 30 was Rs 3,357 crore, against Rs 2,880 crore in the corresponding quarter of FY13, posting a 17 per cent growth.


PTI
New Delhi, October 31, 2013
Revenue from the global generics segment grew 32 per cent to Rs 2,654.78 crore, driven by North America, Russia and other emerging markets, the company said.


BT Online Bureau
Mumbai, October 14, 2013
After gaining 633.49 points in the previous four sessions, the 30-share index of the Bombay Stock Exchange rose 78.95 points, or 0.38 per cent, to 20,607.54.


Reuters
Mumbai, September 13, 2013
Increased on-the-ground oversight reflects India's growing importance as a supplier to the United States, and should ultimately bolster quality and confidence in Indian-made drugs.


PAGES 19 OF 24  1617181920